Adma Biologics (ADMA) Non-Current Debt (2016 - 2025)
Adma Biologics' Non-Current Debt history spans 13 years, with the latest figure at $69.3 million for Q4 2025.
- For Q4 2025, Non-Current Debt fell 4.16% year-over-year to $69.3 million; the TTM value through Dec 2025 reached $69.3 million, down 4.16%, while the annual FY2025 figure was $69.3 million, 4.16% down from the prior year.
- Non-Current Debt reached $69.3 million in Q4 2025 per ADMA's latest filing, down from $70.1 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $144.3 million in Q1 2023 to a low of $69.3 million in Q4 2025.
- Average Non-Current Debt over 5 years is $110.9 million, with a median of $116.0 million recorded in 2023.
- Peak YoY movement for Non-Current Debt: skyrocketed 526.22% in 2021, then tumbled 44.61% in 2024.
- A 5-year view of Non-Current Debt shows it stood at $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then dropped by 8.57% to $130.6 million in 2023, then crashed by 44.61% to $72.3 million in 2024, then decreased by 4.16% to $69.3 million in 2025.
- Per Business Quant, the three most recent readings for ADMA's Non-Current Debt are $69.3 million (Q4 2025), $70.1 million (Q3 2025), and $73.4 million (Q2 2025).